StockData

Capricor Therapeutics vs uniQure

CAPR and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAPR and QURE compare

uniQure is the larger company, worth 2.9 times as much as Capricor Therapeutics ($1.4B against $489M).

Capricor Therapeutics scores higher on the StockData Score (6 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAPRQURE
Size and price
Market cap$489M$1.4B
Share price$8.41$20.78
Change, 1 year50.2%−30.5%
Change, 5 years147%−27.9%
Beta (5Y)0.423.14
Employees231221
StockData Score
Total score6 (better)4
Valuation score1 (better)0
Growth score02 (better)
Performance score00
Health score5 (better)2
Dividend score00
Valuation
P/S–77.2×
P/B2.0× (better)4.4×
FCF yield−23.5%−11.2% (better)
Fair value–$6.42
Margin of safety–−224%
Growth
Revenue growth (TTM)–30.2%
Revenue growth, 5Y average–−15.6%
Profitability
Gross margin–92.5%
Operating margin–−1072%
Net margin–−1351%
FCF margin–−865%
Return on equity−73.7% (better)−158%
Financial health
Debt / equity0.000.15 (better)
Interest coverage–−3.4×
Current ratio7.3510.01 (better)
Altman Z-score0.42 (better)−0.51
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions67.6%96.0%
Held by insiders1.6%2.1%
Insider net buying, 12 months−$8.4M (better)−$20.2M
Short interest, % of float32.8%12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.